Fig. 7.

Effects of NOP and MOP antagonists on antiallodynic effects of intrathecal BU08028 (1 µg), SR16435 (3 µg) and buprenorphine (3 µg) in neuropathic pain at 0.5 hours. Antagonists J-113397 (3 µg), naltrexone (3 µg), or combination of naltrexone and J-113397 (3 µg) were intrathecally administered as a 10-minute pretreatment. Top panels: effects of antagonists on increased paw withdrawal thresholds (g) induced by BU08028 (A), SR16435 (C), and buprenorphine (E). Bottom panels: effects of antagonists on percentage of maximum possible antiallodynic effects of BU08028 (B), SR16435 (D), and buprenorphine (F). *Statistically significant difference from the vehicle control (P < 0.05).